Protalix Biotherapeutics, Inc. 8-K Summary
Business Context and Reporting Period
Protalix Biotherapeutics, Inc. (PLX) filed a Current Report on Form 8-K on August 12, 2026. The filing announces the issuance of a press release containing financial results for the fiscal quarter ended June 30, 2026, along with a business and clinical update.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the source text.
Material Changes
The filing does not provide specific data to compare current period performance against prior comparable periods. Investors must refer to the attached press release (Exhibit 99.1) for details on material changes.
Guidance, Outlook, and Risks
The Company provided a business and clinical update in the referenced press release. The filing includes a standard disclaimer stating that the information in this 8-K and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 12, 2026) for specific Q2 2026 financial figures.
- Verify the details of the business and clinical update mentioned in the press release.
- Confirm the Company's cash position and runway based on the full press release data.
- Check for any new guidance or changes to clinical trial timelines provided in the update.